About Kerry Reynolds, MD

Watch a video about my work

Dr. Kerry Reynolds is a physician at the Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard Medical School. She currently serves as the Director of the Severe Immunotherapy Complications Service, in addition to being the Clinical Director for the inpatient cancer services at Mass General Cancer Center.

Dr. Reynolds specializes in the care of hospitalized patients. Under her leadership, the Massachusetts General Cancer Center’s inpatient program evaluates and treats over 4,000 patients each year and serves as a core training experience for Harvard Medical School students, residents, and fellows each year.

After completing her own residency, chief residency at Massachusetts General, and fellowship training in Oncology at Dana-Farber/Mass General Brigham Cancer Care, she joined the Harvard Medical School faculty in 2014, where she provides clinical care, supervises and educates trainees, participates in administrative affairs, and conducts research on severe toxicities associated with novel immunotherapy agents.

Her short-term academic and primary research focus is to create a clinical database and tissue collection infrastructure to capture the full national history of immune related adverse events (irAEs), and uncover predictors that will identify patients at highest risk for adverse events associated with immunotherapy, or those destined to be refractory.  The overall goal is to characterize these severe clinical presentations, understand the blueprint of cells/molecules driving these clinical presentations, and ultimately develop new therapeutics to improve the treatment of this unique patient population.


Clinical Interests:



MGH Cancer Center, Bartlett Hall
CHX-1 202
55 Fruit Street
Boston, MA 02114
Phone: 617-724-0549
Fax: 617-724-7799

Medical Education

  • MD, University of Missouri Hospitals and Clinics
  • MD, University of Missouri School of Medicine
  • Residency, Massachusetts General Hospital
  • Residency, MGH
  • Fellowship, Dana Farber Cancer Institute
  • Fellowship, MGH

American Board Certifications

  • Medical Oncology, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


We are in the midst of an exciting revolution in the treatment of cancer. By harnessing and enhancing the body’s immune system using novel therapies such as immune checkpoint inhibitors, we can reduce the amount of tumor burden in patients and, in a subset of patients and cancers, achieve long-lasting remission. However, these therapies are often limited by treatment-induced autoimmune adverse events. They affect nearly every organ system, ranging widely from minor rashes and fevers to severe gastrointestinal, pulmonary, or cardiac complications. Dr. Kerry Reynolds, along with Dr. Chloe Villani, and the Massachusetts General Hospital has taken a lead in this arena by altering our clinical practice model to provide expert multi-disciplinary care by creating the Severe Immunotherapy Complications Service. Importantly, this group is not just involved in the clinical care but they have banded together to set up infrastructure to empower specimen collection and facilitate translational research efforts, in order to understand the mechanisms driving immune-related adverse events (irAEs). Blood/tissue samples are systematically collected in an attempt to develop better therapies to treat autoimmune toxicities while maintaining anti-tumor immunity. The hope is that this will further our understanding of early mechanisms leading to autoimmune diseases and identify novel druggable targets with immunosuppressive potential.  The Severe Immunotherapy Complications Service brings together expertise from a variety of clinical divisions and scientists across the institution to coordinate our care and tackle a critical problem facing many cancer patients today. 


  • Selected Publications:

    • Sise ME, Seethapathy H, Reynolds KL. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. Oncologist. 2019 24(6):735-742  PMID: 30902916

      Reynolds KL, Guidon AC. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. Oncologist. 24(4):435-443.(April, 2019). PMID:30482825.

      Reynolds K, Thomas M, Dougan M. Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. Oncologist 23(9):991-997. (2018) PMID: 29853659

      Zubiri L, et al, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy.  Oncologist. 2019 Nov 21. PMID: 31754069

      Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Curr Oncol Rep. 2020 Mar 21; 22(4):39. PMID: 32200442.

      Schoenfeld SR, Aronow ME, Leaf RK, Dougan M, Reynolds KL. Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist. 2020 01; 25(1):6-14. PMID: 31694890.

      Molina GE, Yu Z, Foreman RK, Reynolds KL, Chen ST. Generalized Bullous Mucocutaneous Eruption Mimicking Stevens-Johnson Syndrome in the Setting of Immune Checkpoint Inhibition: A Multicenter Case Series. J Am Acad Dermatol. 2020 Mar 18. PMID: 32199891.